Cargando…
Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
Pancreatic neuroendocrine tumors (PanNENs) are rare sporadic cancers or develop as part of hereditary syndromes. PanNENs can be both functioning and non-functioning based on whether they produce bioactive peptides. Some PanNENs are well differentiated while others—poorly. Symptoms, thus, depend on b...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267066/ https://www.ncbi.nlm.nih.gov/pubmed/32537434 http://dx.doi.org/10.3389/fonc.2020.00831 |
_version_ | 1783541426877890560 |
---|---|
author | Bocchini, Martine Nicolini, Fabio Severi, Stefano Bongiovanni, Alberto Ibrahim, Toni Simonetti, Giorgia Grassi, Ilaria Mazza, Massimiliano |
author_facet | Bocchini, Martine Nicolini, Fabio Severi, Stefano Bongiovanni, Alberto Ibrahim, Toni Simonetti, Giorgia Grassi, Ilaria Mazza, Massimiliano |
author_sort | Bocchini, Martine |
collection | PubMed |
description | Pancreatic neuroendocrine tumors (PanNENs) are rare sporadic cancers or develop as part of hereditary syndromes. PanNENs can be both functioning and non-functioning based on whether they produce bioactive peptides. Some PanNENs are well differentiated while others—poorly. Symptoms, thus, depend on both oncological and hormonal causes. PanNEN diagnosis and treatment benefit from and in some instances are guided by biomarker monitoring. However, plasmatic monoanalytes are only suggestive of PanNEN pathological status and their positivity is typically followed by deepen diagnostic analyses through imaging techniques. There is a strong need for new biomarkers and follow-up modalities aimed to improve the outcome of PanNEN patients. Liquid biopsy follow-up, i.e., sequential analysis on tumor biomarkers in body fluids offers a great potential, that need to be substantiated by additional studies focusing on the specific markers and the timing of the analyses. This review provides the most updated panorama on PanNEN biomarkers. |
format | Online Article Text |
id | pubmed-7267066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72670662020-06-12 Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review Bocchini, Martine Nicolini, Fabio Severi, Stefano Bongiovanni, Alberto Ibrahim, Toni Simonetti, Giorgia Grassi, Ilaria Mazza, Massimiliano Front Oncol Oncology Pancreatic neuroendocrine tumors (PanNENs) are rare sporadic cancers or develop as part of hereditary syndromes. PanNENs can be both functioning and non-functioning based on whether they produce bioactive peptides. Some PanNENs are well differentiated while others—poorly. Symptoms, thus, depend on both oncological and hormonal causes. PanNEN diagnosis and treatment benefit from and in some instances are guided by biomarker monitoring. However, plasmatic monoanalytes are only suggestive of PanNEN pathological status and their positivity is typically followed by deepen diagnostic analyses through imaging techniques. There is a strong need for new biomarkers and follow-up modalities aimed to improve the outcome of PanNEN patients. Liquid biopsy follow-up, i.e., sequential analysis on tumor biomarkers in body fluids offers a great potential, that need to be substantiated by additional studies focusing on the specific markers and the timing of the analyses. This review provides the most updated panorama on PanNEN biomarkers. Frontiers Media S.A. 2020-05-27 /pmc/articles/PMC7267066/ /pubmed/32537434 http://dx.doi.org/10.3389/fonc.2020.00831 Text en Copyright © 2020 Bocchini, Nicolini, Severi, Bongiovanni, Ibrahim, Simonetti, Grassi and Mazza. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bocchini, Martine Nicolini, Fabio Severi, Stefano Bongiovanni, Alberto Ibrahim, Toni Simonetti, Giorgia Grassi, Ilaria Mazza, Massimiliano Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title_full | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title_fullStr | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title_full_unstemmed | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title_short | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review |
title_sort | biomarkers for pancreatic neuroendocrine neoplasms (pannens) management—an updated review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267066/ https://www.ncbi.nlm.nih.gov/pubmed/32537434 http://dx.doi.org/10.3389/fonc.2020.00831 |
work_keys_str_mv | AT bocchinimartine biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT nicolinifabio biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT severistefano biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT bongiovannialberto biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT ibrahimtoni biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT simonettigiorgia biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT grassiilaria biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview AT mazzamassimiliano biomarkersforpancreaticneuroendocrineneoplasmspannensmanagementanupdatedreview |